JAMA Psychiatry
March 1, 2025
Michelle Matvey, Dennis Parker Kelley, Ellen Bradley et al.
12 citations
There is unprecedented clinician, industry, and patient interest in the therapeutic development of psychedelic drugs. This is due to a combination of promising clinical trial results, positive media coverage, and the lack of novel pharmacologic treatments for psychiatric disorders in recent decades. However, the field faces a key methodological challenge: masking participants to treatment...
Neuropsychopharmacology
2024
Tobias Haeusermann, Winston Chiong
New treatment modalities for mental illness are deeply needed, and emerging therapeutic agents such as psychedelics, ketamine, and neuromodulatory technologies have been welcomed by many researchers and patients. These treatment approaches have also been observed to raise novel ethical questions, and to pose new and different versions of familiar ethical questions in clinical treatment and...
Brain
April 9, 2013
Winston Chiong, Stephen M. Wilson, Mark D’Esposito et al.
234 citations
Large-scale brain networks are integral to the coordination of human behaviour, and their anatomy provides insights into the clinical presentation and progression of neurodegenerative illnesses such as Alzheimer's disease, which targets the default mode network, and behavioural variant frontotemporal dementia, which targets a more anterior salience network. Although the default mode network is...
Neurocase
April 18, 2011
Winston Chiong
12 citations
Neuroscientists have recently begun to explore topics, such as the nature of the self, that were previously considered problems for philosophy rather than for science. This article aims to provide a starting point for interdisciplinary exchange by reviewing three philosophical debates about the nature of the self in light of contemporary work in cognitive neuroscience. Continental rationalist...